

Supplementary Table S1. Biochemical parameters of enrolled subjects.

	Reference Value	Median (IQR)	Range (min–max)
Red blood cell count ($\times 10^4/\mu\text{L}$)	435–555	389 (366–439)	253–552
Hemoglobin (g/dL)	13.7–16.8	11.2 (9.8–12.7)	6.9–16.5
White blood cell count ($/\mu\text{L}$)	3300–8600	7000 (3400–8600)	3200–18,000
Platelet count ($\times 10^3/\text{mm}^3$)	15.8–34.8	274 (223–375)	127–622
AST (IU/L)	13–30	25 (18.5–38)	8–315
ALT (IU/L)	10–30	18 (12–28)	4–277
LDH (IU/L)	124–222	212 (168.5–343.5)	106–2,323
ALP (IU/L)	115–359	284 (223.5–479.5)	78–3,911
GGT (IU/L)	13–64	33 (17–108)	9–1,071
Total protein (g/dL)	6.6–8.1	6.78 (6.4–7.21)	4.95–8.1
Albumin (g/dL)	4.1–5.1	3.5 (3.12–3.86)	1.8–4.85
Prothrombin activity (%)	80–120	98.5 (88.7–107)	21.7–130
Total bilirubin (mg/dL)	0.40–1.20	0.51 (0.41–0.7)	0.25–4.64
Total cholesterol (mg/dL)	142–219	169 (142.8–199)	94–291
Triglyceride (mg/dL)	40–149	96 (75–121)	41–314
BUN (mg/dL)	8.0–20.0	13.4 (11.6–18.0)	7–164
Creatinine (mg/dL)	0.65–1.07	0.77 (0.64–0.94)	0.32–6.15
eGFR (mL/min/1.73 m ²)	>90.0	72.4 (60.7–85.2)	6.1–141.3
Blood glucose (mg/dL)	80–109	105.5 (97–125)	72–288
HbA1c (%)	4.3–5.8	5.9 (5.5–6.2)	3.9–10.9
CEA	≤ 5.0	8.5 (3.5–32.6)	0.3–2,868
CA19-9	≤ 37.0	24.4 (7.05–95.9)	1–109,278

Note: Data are expressed as median (interquartile range [IQR]), range, or frequency. Abbreviations: IQR, interquartile range; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; CEA, carcinoembryonic antigen.

Supplementary Table S2. Comparison of biochemical parameters between the Alive and Deceased groups.

	Alive		Deceased		<i>p</i>
	Median (IQR)	Range (Min–Max)	Median (IQR)	Range (Min–Max)	
Red blood cell count (×10 ⁴ /μL)	389 (354–430)	270–552	389 (367–443)	253–528	0.6102
Hemoglobin (g/dL)	11.2 (9.8–12.3)	7.0–15.3	11.4 (9.8–12.7)	6.9–16.5	0.9089
White blood cell count (/μL)	6,700 (5,600–8,100)	4,000–13,600	7,100 (6,200–8,700)	3,200–18,000	0.2195
Platelet count (×10 ³ /mm ³)	261 (223–372)	154–462	280 (221–375)	127–622	0.7366
AST (IU/L)	22 (18.3–34.5)	12–56	26 (18.5–38.5)	8–315	0.6271
ALT (IU/L)	20 (13.3–25.8)	5–48	17 (11–32)	4–277	0.8759
ALP (IU/L)	269 (212–374)	148–1,262	293 (224–541)	78–3,911	0.3617
GGT (IU/L)	29 (18–66)	10–365	37 (16–119)	9–1071	0.6396
Total protein (g/dL)	6.99 (6.43–7.49)	5.10–8.10	6.75 (6.39–7.70)	4.95–8.00	0.1561
Prothrombin activity (%)	95 (86–103)	22–127	99 (92–108)	54–130	0.1203
Total bilirubin (mg/dL)	0.50 (0.40–0.70)	0.25–3.40	0.55 (0.42–0.71)	0.25–4.64	0.6037
Total cholesterol (mg/dL)	166 (136–187)	111–235	169 (147–206)	94–291	0.1747
Triglyceride (mg/dL)	93 (70–122)	54–149	99 (75–121)	41–314	0.6798
BUN (mg/dL)	13.7 (11.5–20.8)	7–35.1	13.4 (11.6–17.8)	8–164	0.7734
Creatinine (mg/dL)	0.79 (0.68–0.94)	0.49–5.96	0.75 (0.63–0.94)	0.32–6.15	0.4051
eGFR (mL/min/1.73 m ²)	71.3 (62.9–83.5)	6.1–103.6	72.4 (60.5–89.6)	7.7–141.3	0.5485
Blood glucose (mg/dL)	104 (95–111)	72–158	108 (100–132)	79–288	0.1219
CEA	8.0 (3.2–19.3)	0.7–345	8.5 (3.7–55.2)	0.3–2,868	0.4580
CA19-9	17.1 (5.4–68.8)	2–109,278	27.0 (7.6–111.5)	1–88,806	0.3709

Note: Data are expressed as median (interquartile range [IQR]), range, or frequency. Abbreviations: IQR, interquartile range; SOX, S-1 with oxaliplatin; SP, S-1 with cisplatin; FOLFOX, 5-fluorouracil with oxaliplatin; Cape, capecitabine; 5-FU, 5-fluorouracil; SOXT, S-1 with oxaliplatin and trastuzumab; SPT, S-1 with cisplatin and trastuzumab; CAPOXT, capecitabine with oxaliplatin and trastuzumab; XPT, capecitabine with cisplatin and trastuzumab; tub, tubular adenocarcinoma; por, poorly differentiated adenocarcinoma; sig, signet-ring cell carcinoma; muc, mucinous adenocarcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; CEA, carcinoembryonic antigen; NLR, neutrophil-to-lymphocyte ratio.